Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) advancing by 0.4%.
BridgeBio Pharma (BBIO) stock was up more than 3% after the company said it met the primary endpoint in a phase 3 trial of the oral drug infigratinib, for the treatment of children living with achondroplasia, or bone dwarfism.